# Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

> **NCT00439556** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- CD20 Positive
- Hematopoietic and Lymphoid Cell Neoplasm
- Lymphocytic Neoplasm
- Lymphoma

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Anti-Thymocyte Globulin
- **DRUG:** Bortezomib
- **DRUG:** Carmustine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Melphalan
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Rituximab
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00439556
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-13
- **Primary completion:** 2018-06-07
- **Final completion:** 2018-06-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439556, "Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00439556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*